# OnCo record nct06581406 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06581406/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06581406", "NCT06581406" ;
  schema:name "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P"@en ;
  schema:description "A phase 2/3 trial of Ipilimumab, Nivolumab in melanoma and uveal melanoma, run by Replimune, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06581406/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06581406> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2024-12-17" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/uveal-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/replimune/> .